Advertisement

Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 600x60px
Document › Details

Shimadzu Corporation. (4/27/17). "Press Release: New Method for Early Screening of Colorectal Cancer".

Region Region Japan
Organisations Organisation Shimadzu Corporation
  Group Shimadzu (Group)
  Organisation 2 Kobe University
Products Product cancer test, early detection
  Product 2 GC/MS (gas chromatography/mass spectrometry)
Persons Person Yoshida, Masaru (Kobe Univ 201704 Associate Professor Graduate School of Medicine)
  Person 2 Ojima, Norijyuki (Shimadzu 201704 Manager of Analytical + Measuring Instruments Division)
     


A highly sensitive method that can detect even the earlier stages of colorectal cancer has been developed by researchers in Japan. Shimadzu Corporation, the Kobe University Graduate School of Medicine, and the National Cancer Center in Japan have collaborated to develop a new screening method that comprehensively analyzes the metabolites in our blood. The results of this research were published in the online edition of Oncotarget, a U.S. scientific publication, on February 4, 2017.

Colorectal cancer is one of the most common causes of cancer death, and cases of this cancer are increasing in developed countries. In 2012, a group headed by Associate Professor YOSHIDA Masaru at Kobe University used gas chromatography-mass spectrometry (GC/MS) and clinical metabolomic analysis methods to analyze serum samples from colorectal cancer patients and healthy subjects. The group succeeded in identifying four metabolite markers that can be used to diagnose colorectal cancer and developed a highly reliable diagnostic prediction model using those markers. This model was considered to be more practical in comparison with existing tumor markers, but it lacked sensitivity and specificity when actually used as a screening method.

Following this, a research team combining members from Shimadzu Corporation and Kobe University developed an analytical approach that enabled much more accurate measurement of metabolites in blood plasma. To achieve this, they used high-speed and high-sensitivity GC-MS/MS, which relies on Shimadzu's Advanced Scanning Speed Protocol (ASSP) and Smart MRM technologies.

By using this approach to analyze a large number of samples (at least 600) with known clinical data stored at the National Cancer Center, they were able to develop a high-performance screening method. After reviewing the results of comprehensive analyses of the metabolites contained in blood plasma from colorectal cancer patients and healthy subjects, they discovered eight multi-biomarkers that can be used to diagnose colorectal cancer.

Based on the data for these eight metabolites, they were able to create a diagnostic prediction model for colorectal cancer that exceeded 96% for both sensitivity and specificity. They also confirmed that the sensitivity of this new model remained at high levels even with early-stage colorectal cancer patients (stage 0 and stage I).

This research was conducted with support by the following grant program of the Japan Agency for Medical Research and Development (AMED):


Medical Research and Development Programs Focused on Technology Transfer (SENTAN) (Development theme: Practical implementation of a fully automatic screening system for very early stage diagnosis of colorectal cancer)
Team leader: Noriyuki Ojima, Manager of Analytical & Measuring Instruments Division, Shimadzu Corporation
Sub-leader: Masaru Yoshida, Associate Professor, Kobe University Graduate School of Medicine

> Selected in FY 2013 by the Japan Science and Technology Agency (JST) as a JST-SENTAN Program (Development of Advanced Measurement and Analysis Systems), and transferred to an AMED program in April 2015.


Paper Information
Paper
Investigations in the possibility of early detection of colorectal cancer by gas chromatography/triple-quadrupole mass spectrometry

Authors
Shin Nishiumi*, Takashi Kobayashi*, Shuichi Kawana, Yumi Unno, Takero Sakai, Koji Okamoto, Yasuhide Yamada, Kazuki Sudo, Taiki Yamaji, Yutaka Saito, Yukihide Kanemitsu, Natsuko Tsuda Okita, Hiroshi Saito, Shoichiro Tsugane, Takeshi Azuma, Noriyuki Ojima, Masaru Yoshida
(*,contributed equally to this study and shared authorship)

Journal
Oncotarget Advanced Publications 2017

DOI:10.18632/oncotarget.15081

   
Record changed: 2017-06-10

Advertisement

Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 600x60px

More documents for Shimadzu (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture EBD Group BioPharm America 2017 BPA Boston MA September 600x60px




» top

Advertisements

Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 120x180px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px 22 Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 120x180px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px 40